Rokitansky Syndrome (MRKH) and Uterine Absence: A Comprehensive UK Guide to Surrogacy and Biological Motherhood

Receiving a diagnosis of absolute uterine factor infertility (AUFI) —whether through a congenital condition such as Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome or an acquired surgical hysterectomy— can be a devastating moment for women in the UK aspiring to build a family. Historically, the absence of a functional uterus meant that carrying a pregnancy was biologically impossible, leaving adoption as the sole pathway to parenthood.

However, modern advancements in reproductive medicine combined with the UK’s legal framework for gestational surrogacy for gay now provide a reliable route to biological motherhood. Women with MRKH possess fully functional ovaries, meaning their genetic material can be used in an In Vitro Fertilisation (IVF) cycle to create embryos that are subsequently carried by a surrogate.

MRKH Syndrome and Absolute Uterine Factor Infertility (AUFI)

To understand why surrogacy is the primary medical solution for MRKH and structural uterine conditions, it is essential to distinguish between the uterine factor and overall reproductive capacity.

Women diagnosed with MRKH Type 1 present with isolated uterovaginal aplasia, while those with MRKH Type 2 may have associated renal or skeletal variations. In both instances, ovarian development proceeds normally from the intermediate mesoderm rather than the Müllerian ducts. Consequently, hormonal output (estrogen and progesterone), follicular maturation, and anti-Müllerian hormone (AMH) levels typically mirror those of age-matched women without MRKH.

Clinical Pathway: Autologous IVF & Transfer

Because ovarian function is intact, intended mothers in the UK can undergo an autologous IVF protocol (using their own oocytes). The clinical workflow involves three distinct phases:

1. Controlled Ovarian Hyperstimulation: The intended mother receives gonadotropin injections to stimulate multiple follicular developments. Oocytes are harvested via ultrasound-guided transvaginal aspiration or, in cases of elevated ovarian positioning due to MRKH, laparoscopic retrieval.
2. In Vitro Fertilization & Culture: Retrieved oocytes are fertilised using Intracytoplasmic Sperm Injection (ICSI) with the partner’s or donor’s sperm. Embryos are cultured to the blastocyst stage (Day 5/6).
3. Endometrial Preparation of the Surrogate: The surrogate undergoes hormonal preparation to ensure an optimal endometrial thickness before a single blastocyst transfer is executed.

Comparative Matrix: Reproductive Routes for Uterine Absence in the UK

To evaluate the available options, the table below compares the primary pathways open to UK patients presenting with MRKH or surgical uterine loss:

The UK Legal Framework: Parental Orders & Surrogacy Law Reform

Navigating surrogacy in the UK requires a clear understanding of the legal landscape. Under the Surrogacy Arrangements Act 1985 and the Human Fertilisation and Embryology Act 2008 (Section 54), commercial surrogacy contracts are unenforceable.

Key Legal Considerations for UK Intended Parents:

• Initial Legal Status: At birth, the surrogate (and her spouse, if applicable) is registered as the child’s legal parent under UK law, regardless of where the child is born.
• The Parental Order (Section 54): Intended parents must apply for a Parental Order in the UK Family Court within 6 months of birth. This order extinguishes the surrogate’s legal parental rights and reassigns full parental status to the intended parents, resulting in the issuance of a UK birth certificate.
• Requirements for a Parental Order:
  1. At least one intended parent must provide genetic material (satisfied via MRKH autologous oocytes or partner sperm).
  2. The child must reside with the intended parents at the time of application.
  3. The surrogate must freely consent to the order no sooner than 6 weeks post-delivery.
  4. Only reasonable expenses may be paid to the surrogate, unless authorized retrospectively by the court.

Law Commission Surrogacy Reforms

The Law Commission of England and Wales, along with the Scottish Law Commission, released joint reform proposals aimed at creating a “new pathway” for UK surrogacy. This pathway allows intended parents to become legal parents from birth subject to pre-conception safeguards, streamlining the historical legal hurdles for families affected by conditions like MRKH.

Real Scientific, Medical, and Legal Sources

1. British Journal of Obstetrics and Gynaecology (BJOG): Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: diagnosis, management and reproductive options. Official publication of the Royal College of Obstetricians and Gynaecologists (RCOG).
2. Orphanet International: Mayer-Rokitansky-Küster-Hauser syndrome (ORPHA:99429). Epidemiological data and clinical classification.
3. UK Legislation / National Archives: Human Fertilisation and Embryology Act 2008, Section 54 (Parental Orders) & Surrogacy Arrangements Act 1985.
4. Law Commission of England and Wales: Reforming Surrogacy Law (Joint Report Law Com No 411 / SLC No 262).
5. Human Fertilisation and Embryology Authority (HFEA): Code of Practice & Third-Party Reproduction Guidelines for UK Clinics.
6. Fertility and Sterility (ASRM Journal): Obstetric and neonatal outcomes of gestational surrogacy in absolute uterine factor infertility.